TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Spectral power density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of low back pain resulting in seeking health care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: minutes of moderate‐intensity activity/week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to complete the one‐mile walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean maximum pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dQTc value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BCVA change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative pain at 8 h and 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrist or forearm motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean daily glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose readings <140 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose <70 mg/dL
Endpoint domain: Adverse events/effects
Primary endpoint: VAS for pain during movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS for morning stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Finger systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temperature recovery after cold immersion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of dapagliflozin in heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of dapagliflozin in heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants achieving the primary endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of the post-test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Smoking abstinence at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: BMD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Merle d'Aubigné score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nottingham Health Profile
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FSFI total score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: orgasm domain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arousal domain score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intravenous fluid volume until delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ephedrine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reported complaints of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: mean minutes of overall vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean minutes of school day moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean minutes of school day vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of neonatal withdrawal treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: faster voluntary step execution times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved self‐reported lower extremity function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: microbial plaque composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microsomal liver function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or BPD at 36 weeks' postmenstrual age
Endpoint domain: Mortality/survival
Primary endpoint: Treatment refusals recorded in Joint Crisis Plans
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-bronchodilator FEV1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: residual volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the concentration‐versus‐time curve of inorganic serum phosphate (AUC(0‐24))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum concentration of inorganic phosphate in serum (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total amount of inorganic phosphate excreted in urine over 24 h (Ae(0‐24 bc))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Development Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychomotor Development Index
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ataxia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Dizziness incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Dry mouth incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Best-Corrected Visual Acuity (BCVA) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity in predicting seminomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity in predicting seminomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with social contact
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Adverse effects observed
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive/developmental function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GPX enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SOD enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxygen uptake (VO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum total point motion (MTPM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of continuously migrating tibial plates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wormald grading scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute allograft rejection episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median BCVA improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean CCT return to preoperative level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean ECD loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived behavioral control (PBC) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: self-reported walking behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of thinness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Confirmed abstinence at 6-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV diastolic function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: glucose metabolic clearance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BIS index during maintenance of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedures rated as excellent or good
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depth of sigmoidoscope insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedures rated as discomfort free
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean morning peak expiratory flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lifetime Relationship status
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Independent living
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Wearing comfort and tolerability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: average extent of union on CT at 10 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to TB treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activated coagulation time (ACT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of heparin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained abstinence during BUP-NLX taper
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: vascular attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: subjective image quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Clinicians' diagnostic confidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home Dim Light Melatonin Onset (DLMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: resting oxygen uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean serum urate (SU) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SF-12 Physical Component Scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of recurrent herniation
Endpoint domain: Adverse events/effects
Primary endpoint: Target-vessel-failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: In-segment late lumen loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arterial lactate level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postoperative pain score (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder tip pain incidence
Endpoint domain: Adverse events/effects
Primary endpoint: stimulation following alcohol consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of urothelial cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of renal cell cancer
Endpoint domain: Mortality/survival
Primary endpoint: EULAR response at Week 10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EULAR response at Week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DAS28‐ESR score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coronary heart disease risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: light transmission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in sunburns
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: overall average daily pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: engagement in risk behaviors
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: gang involvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sexual violence exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-1ra mean values post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 mean values post-operatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement in meibomian gland expressibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MGD stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final favorable anatomic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable regression of ROP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No recurrence of neovascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean annual non-antiretroviral-related costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Difference in Spo2 readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failure of repair
Endpoint domain: Adverse events/effects
Primary endpoint: Recurrence of CSF leak
Endpoint domain: Adverse events/effects
Primary endpoint: J-index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DeltaPP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Connective tissue alterations in skin biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: total number of subjects with back or lower extremity problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of subjects with shin splints
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of off‐duty days because of back or lower extremity problems
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: AHI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: 5-min uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: BPSN score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3/4 neutropenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of all-grade adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of grade 3/4 drug-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Any hypoglycemic event
Endpoint domain: Adverse events/effects
Primary endpoint: Major hypoglycemic event
Endpoint domain: Adverse events/effects
Primary endpoint: Epithelial histology improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in nasal mucosal eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in nasal mucosal basophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of postoperative adhesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score during and after dressing change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carotid IMT (arterial wall thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in corrected serum calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relapse rate at 18 months
Endpoint domain: Mortality/survival
Primary endpoint: need for intraaortic balloon pumps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: need for inotropic agents
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean area under the GIR curve over 24 h (AUC(GIR,0-24 h))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean maximum GIR (GIR(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Forward digit spans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Backward digit spans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SGRQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Exercise capacity improvement (12 min walk test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocolytic effectiveness at 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tocolytic efficacy and tolerability after 48 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in diagnosing pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in treating pneumothorax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete treatment time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: resilience mean scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: D2-receptor occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to pain progression (TTPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate-specific antigen (PSA) declines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first major cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 3-year event-free survival (FFS)
Endpoint domain: Mortality/survival
Primary endpoint: Mean intraarticular temperature change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total weight loss (TWL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute infarct size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: myocardial area at risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: perceived exertion
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: observer stability assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of RA and related metabolites excreted in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall sexual function
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lactase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Control rates at day 45
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean medication use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: RQLQ, Morisky, and B-IPQ score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to hospital discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to start a soft diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Re-hospitalization rate
Endpoint domain: Adverse events/effects
Primary endpoint: in-hospital heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity for polyp detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cognitive control performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dietary supplement usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: adverse skin reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Mean reduction in intraocular pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Drug cost savings
Endpoint domain: Resource use
Primary endpoint: Compliance with dosing guidelines
Endpoint domain: Physiological/clinical